Updates are available Correction dated 2024-11-20
Click to view Correction: https://doi.org/10.1038/s41588-024-02034-9
-
Authors
Li, Carman Man-Chung https://orcid.org/0000-0002-0577-7797
Cordes, Alyssa https://orcid.org/0009-0008-0644-8136
Oliphant, Michael U. J.
Quinn, S. Aidan
Thomas, Mayura
Selfors, Laura M.
Silvestri, Francesca https://orcid.org/0000-0003-2540-8267
Girnius, Nomeda https://orcid.org/0000-0002-7267-5950
Rinaldi, Gianmarco
Zoeller, Jason J.
Shapiro, Hana
Tsiobikas, Christina
Gupta, Kushali P.
Pathania, Shailja
Regev, Aviv https://orcid.org/0000-0003-3293-3158
Kadoch, Cigall https://orcid.org/0000-0002-4058-5985
Muthuswamy, Senthil K.
Brugge, Joan S. https://orcid.org/0000-0002-2547-4814
-
Funding
Funding for this research was provided by:
Susan G. Komen
Croucher Foundation
- License Information
-
More Information
Article History
Received: 4 December 2023
Accepted: 23 September 2024
First Online: 11 November 2024
Change Date: 20 November 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41588-024-02034-9
Competing interests
: A.R. is a cofounder of and equity holder in Celsius Therapeutics and an equity holder in Immunitas; she was a scientific advisory board member for Thermo Fisher Scientific, Syros Pharmaceuticals, Neogene Therapeutics and Asimov until 31 July 2020. A.R. has been an employee of Genentech (a member of the Roche Group) since August 2020 and holds equity in Roche. None of these affiliations represent competing interests regarding the present study. The other authors declare no competing interests.
